The tumor mutational burden market is projected to grow from USD 2,081.0 million in 2026 to USD 6,757.7 million by 2036, at a CAGR of 12.5%. Targeted NGS TMB panels will dominate with a 26.0% market share, while immunotherapy patient selection will lead the applications segment with a 34.0% share.